Celldex Therapeutics (CLDX) Capital Expenditures (2010 - 2026)

Celldex Therapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 518.49% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $4.1 million (up 122.17% YoY), while the FY2025 annual figure was $2.7 million, up 41.43% from the prior year.
• Capital Expenditures for Q1 2026 stood at $1.6 million, up from $1.3 million in the prior quarter.
• The five-year high for Capital Expenditures was $1.6 million in Q1 2026, with the low at $157000.0 in Q3 2023.
• The 5-year median for Capital Expenditures is $545000.0 (2024), against an average of $583411.8.
• The sharpest annual moves came in 2023 and 2026: Capital Expenditures tumbled 54.49% in 2023, then surged 518.49% in 2026.
• Celldex Therapeutics' Capital Expenditures stood at $235000.0 in 2022, then jumped by 183.4% to $666000.0 in 2023, then advanced by 13.51% to $756000.0 in 2024, then soared by 69.44% to $1.3 million in 2025, then advanced by 27.95% to $1.6 million in 2026.
• Business Quant data shows CLDX's Capital Expenditures at $1.6 million in Q1 2026, $1.3 million in Q4 2025, and $440000.0 in Q3 2025.